BMI and Ovarian Function are Associated with Endocrine and Metabolic Abnormalities in Women with PCO-Syndrome – Metabolic risks in hyperandrogenic women

Cupisti, S.; Kajaia, N.; Dittrich, Rosângela Locatelli; Duezenli, H; Beckmann, Michael; Mueller, A.

doi:10.1055/s-0028-1089022

Cited by 2 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, central obesity can be diagnosed clinically by measuring the waist circumference (WC) larger than 88 cm or waist-to-hip circumference ratio (WHR) greater than 0.85, confer high risk for metabolic complications in obese individuals with BMI between 25.0 and 34.9 kg/m 2 . However, obesity is a common finding in women with PCOS and between 40-80% of women with this condition is reported to be overweight, obese or centrally obese depending on the setting of the study and the ethnical background of the subjects [53][54][55]. Obesity has a worse additive effect on features of PCOS such as insulin resistance, hyperandrogenism, infertility, hirsutism and pregnancy complications [56].…”

Section: Obesity and Pcosmentioning

confidence: 99%

Polycystic Ovary Syndrome

2018

Obstetrics &Amp; Gynecology

157

View full text Add to dashboard Cite

Polycystic ovary syndrome (PCOS) is a disorder characterized by hyperandrogenism, ovulatory dysfunction, and polycystic ovaries. Its etiology remains unknown, and treatment is largely symptom based and empirical. PCOS has the potential to cause substantial metabolic sequelae, including an increased risk of diabetes and cardiovascular disease, and these factors should be considered when determining long-term treatment. The purpose of this document is to examine the best available evidence for the diagnosis and clinical management of PCOS.

show abstract

Section: Obesity and Pcosmentioning

confidence: 99%

Polycystic Ovary Syndrome

2018

Obstetrics &Amp; Gynecology

157

View full text Add to dashboard Cite

show abstract

“…Metabolic diseases have been related with abnormal levels of this protein in plasma. In obesity, circulating SHBG levels are decreased to 50% in obese adult women (nonmenopause) compared with lean control patients [121,122]. Also, girls and boys with obesity have near 70% of circulating SHBG compared with nonobese [116].…”

Section: Human Diseases and Medications Related Tomentioning

confidence: 98%

Classic and Novel Sex Hormone Binding Globulin Effects on the Cardiovascular System in Men

Basualto-Alarcón

García‐Rivas

Troncoso

et al. 2021

International Journal of Endocrinology

View full text Add to dashboard Cite

In men, 70% of circulating testosterone binds with high affinity to plasma sex hormone binding globulin (SHBG), which determines its bioavailability in their target cells. In recent years, a growing body of evidence has shown that circulating SHBG not only is a passive carrier for steroid hormones but also actively regulates testosterone signaling through putative plasma membrane receptors and by local expression of androgen-binding proteins apparently to reach local elevated testosterone concentrations in specific androgen target tissues. Circulating SHBG levels are influenced by metabolic and hormonal factors, and they are reduced in obesity and insulin resistance, suggesting that SHBG may have a broader clinical utility in assessing the risk for cardiovascular diseases. Importantly, plasma SHBG levels are strongly correlated with testosterone concentrations, and in men, low testosterone levels are associated with an adverse cardiometabolic profile. Although obesity and insulin resistance are associated with an increased incidence of cardiovascular disease, whether they lead to abnormal expression of circulating SHBG or its interaction with androgen signaling remains to be elucidated. SHBG is produced mainly in the liver, but it can also be expressed in several tissues including the brain, fat tissue, and myocardium. Expression of SHBG is controlled by peroxisome proliferator-activated receptor γ (PPARγ) and AMP-activated protein kinase (AMPK). AMPK/PPAR interaction is critical to regulate hepatocyte nuclear factor-4 (HNF4), a prerequisite for SHBG upregulation. In cardiomyocytes, testosterone activates AMPK and PPARs. Therefore, the description of local expression of cardiac SHBG and its circulating levels may shed new light to explain physiological and adverse cardiometabolic roles of androgens in different tissues. According to emerging clinical evidence, here, we will discuss the potential mechanisms with cardioprotective effects and SHBG levels to be used as an early metabolic and cardiovascular biomarker in men.

show abstract

BMI and Ovarian Function are Associated with Endocrine and Metabolic Abnormalities in Women with PCO-Syndrome – Metabolic risks in hyperandrogenic women

Cited by 2 publications

References 0 publications

Polycystic Ovary Syndrome

Polycystic Ovary Syndrome

Classic and Novel Sex Hormone Binding Globulin Effects on the Cardiovascular System in Men

Contact Info

Product

Resources

About